认知功能正常的患者要求进行阿尔茨海默病检测时会问：“我会得阿尔茨海默病吗？”
"Will I get Alzheimer disease?" when cognitively normal patients ask to be tested for Alzheimer disease.
作者信息
Snider B Joy, Buckles Virginia D
机构信息
Washington University, Campus Box 8111 BT 229, 660 S Euclid Ave, St Louis, MO 63110, USA.
出版信息
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):470-4. doi: 10.1212/01.CON.0000429171.50686.07.
Abstract
This article presents the case of a cognitively normal patient who is requesting a procedure (amyloid imaging) recently approved for the diagnosis of Alzheimer disease (AD) in patients with cognitive impairment. The predictive value of this test in unaffected people is not clearly established. Knowing the results of the test will have no effect on therapeutic options, although the patient may make lifestyle decisions based on the results. There is potential risk to the patient in terms of insurability, employability, and psychological consequences. Physicians will face this situation with increasing frequency as the AD biomarker field progresses.
摘要
本文介绍了一例认知功能正常的患者，该患者要求进行一项最近被批准用于诊断认知障碍患者阿尔茨海默病（AD）的检查（淀粉样蛋白成像）。该检查在未受影响人群中的预测价值尚未明确确立。尽管患者可能会根据检查结果做出生活方式的决定，但了解检查结果对治疗选择并无影响。在保险可及性、就业能力和心理影响方面，患者存在潜在风险。随着AD生物标志物领域的发展，医生将越来越频繁地面临这种情况。
相似文献
1
"Will I get Alzheimer disease?" when cognitively normal patients ask to be tested for Alzheimer disease.认知功能正常的患者要求进行阿尔茨海默病检测时会问：“我会得阿尔茨海默病吗？”
Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):470-4. doi: 10.1212/01.CON.0000429171.50686.07.
2
The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.阿尔茨海默病评估量表认知部分在预测遗忘型轻度认知障碍进展为阿尔茨海默病中的重要性。
J Geriatr Psychiatry Neurol. 2008 Dec;21(4):261-7. doi: 10.1177/0891988708324940.
3
Medical decision-making in neurodegenerative disease: mild AD and PD with cognitive impairment.神经退行性疾病中的医学决策：轻度阿尔茨海默病和伴有认知障碍的帕金森病
Neurology. 2005 Aug 9;65(3):483-5. doi: 10.1212/01.wnl.0000171346.02965.80.
4
A data-driven model of biomarker changes in sporadic Alzheimer's disease.散发性阿尔茨海默病生物标志物变化的数据驱动模型。
Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.
5
Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease.采用新型线索回忆测试对轻度认知障碍和阿尔茨海默病患者进行记忆评估。
J Neurol. 2005 Jan;252(1):47-55. doi: 10.1007/s00415-005-0597-2.
6
Preclinical vascular cognitive impairment and Alzheimer disease: neuropsychological test performance 5 years before diagnosis.临床前血管性认知障碍和阿尔茨海默病：诊断前5年的神经心理学测试表现
Stroke. 2007 Apr;38(4):1148-53. doi: 10.1161/01.STR.0000259716.04739.60. Epub 2007 Feb 22.
7
Clinical utility of the K-T cancellation test in a memory clinic population.K-T 抵消试验在记忆门诊人群中的临床应用价值。
J Clin Exp Neuropsychol. 2016 Dec;38(10):1094-102. doi: 10.1080/13803395.2016.1196164. Epub 2016 Jun 28.
8
Subthreshold Amyloid Predicts Tau Deposition in Aging.亚阈值淀粉样蛋白可预测衰老中的 Tau 沉积。
J Neurosci. 2018 May 9;38(19):4482-4489. doi: 10.1523/JNEUROSCI.0485-18.2018. Epub 2018 Apr 23.
9
Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer´s disease: a longitudinal study.主观认知下降、轻度认知障碍和阿尔茨海默病患者对气味、面孔、城市和物体命名的识别：一项纵向研究。
Int Psychogeriatr. 2019 Apr;31(4):537-549. doi: 10.1017/S1041610218001114. Epub 2018 Sep 21.
10
Usefulness of Discriminability and Response Bias Indices for the Evaluation of Recognition Memory in Mild Cognitive Impairment and Alzheimer Disease.辨别力和反应偏差指数在轻度认知障碍和阿尔茨海默病识别记忆评估中的效用
Dement Geriatr Cogn Disord. 2017;43(1-2):1-14. doi: 10.1159/000452255. Epub 2016 Nov 26.
引用本文的文献
1
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials.显性遗传阿尔茨海默病网络：推动研究与临床试验
Alzheimers Res Ther. 2013 Oct 17;5(5):48. doi: 10.1186/alzrt213. eCollection 2013.
本文引用的文献
1
Risk estimations, risk factors, and genetic variants associated with Alzheimer's disease in selected publications from the Framingham Heart Study.与弗雷明汉心脏研究中部分出版物相关的阿尔茨海默病的风险评估、风险因素和遗传变异。
J Alzheimers Dis. 2013;33 Suppl 1(0 1):S439-45. doi: 10.3233/JAD-2012-129040.
2
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.采用氟[18F]氟比他滨 PET 评估淀粉样蛋白-β与 18 个月认知衰退的相关性：一项多中心研究。
Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11.
3
Florbetapir: knowing one's future.氟代硼吡咯：知晓个人未来。
Ann Neurol. 2012 Jun;71(6):A6. doi: 10.1002/ana.23646.
4
Molecular neuroimaging in Alzheimer's disease.阿尔茨海默病的分子神经影像学。
Neuroimaging Clin N Am. 2012 Feb;22(1):57-65, viii. doi: 10.1016/j.nic.2011.11.005. Epub 2011 Dec 6.
5
CSF biomarkers for Alzheimer's disease: current utility and potential future use.阿尔茨海默病的脑脊液生物标志物：当前的应用及潜在的未来应用。
Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S4-9. doi: 10.1016/j.neurobiolaging.2011.09.003.
6
Use of florbetapir-PET for imaging beta-amyloid pathology.氟代脱氧葡萄糖-PET 用于成像β淀粉样蛋白病理。
JAMA. 2011 Jan 19;305(3):275-83. doi: 10.1001/jama.2010.2008.
7
Experience over fifteen years with a protocol for predictive testing for Huntington disease.对亨廷顿病预测性检测方案的十五年经验。
Mol Genet Metab. 2011 Apr;102(4):494-504. doi: 10.1016/j.ymgme.2010.12.001. Epub 2010 Dec 13.
8
Autobiographical memory task in assessing dementia.评估痴呆症的自传体记忆任务。
Arch Neurol. 2010 Jul;67(7):862-6. doi: 10.1001/archneurol.2010.145.
9
"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate.“我知道你告诉过我，但这是我的想法：”那些能准确回忆起基于遗传风险评估的人对阿尔茨海默病风险的感知。
Genet Med. 2010 Apr;12(4):219-27. doi: 10.1097/GIM.0b013e3181cef9e1.
10
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.在认知正常的个体中，脑脊液 tau 和 ptau(181)随着皮质淀粉样沉积的增加而增加：对未来阿尔茨海默病临床试验的影响。
EMBO Mol Med. 2009 Nov;1(8-9):371-80. doi: 10.1002/emmm.200900048.
Zotero 插件